Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to find out whether or not the combination of NOV-002
with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time
when compared to chemotherapy alone in people with non-small cell lung cancer (NSCLC).
Earlier clinical trials in NSCLC showed that patients treated with NOV-002 in combination
with chemotherapy had a better response (their tumors got smaller in one United States Phase
1/2 trial) than patients who received chemotherapy alone; and in two Phase 2 trials done in
Russian patients, at the end of one year, patients treated with NOV-002 with chemotherapy had
a better survival rate than patients who did not receive NOV-002 with their chemotherapy.